K2 Principal Fund’s Deep Medicine Acquisition Corp. Rights DMAQR Stock Holding History

K2 Principal Fund’s Portfolio DMAQR Stock Details DMAQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-134,514	Closed	-$40.4K	–	340
2023 Q4	$40.4K	Sell	134,514 -145,847	-52%	-$45.1K	0.01%	179
2023 Q3	$97.8K	Buy	280,361 +113,779	+68%	+$30K	0.02%	150
2023 Q2	$23.3K	Sell	166,582 -87,608	-34%	-$14.3K	0.01%	167
2023 Q1	$36.9K	Sell	254,190 -101,000	-28%	-$10.2K	0.01%	199
2022 Q4	$21.3K	Sell	355,190 -119,810	-25%	-$6.85K	﹤0.01%	190
2022 Q3	$19K	Hold	475,000	–	–	﹤0.01%	246
2022 Q2	$52K	Hold	475,000	–	–	0.01%	282
2022 Q1	$85K	Hold	475,000	–	–	0.01%	239
2021 Q4	$152K	Buy	+475,000	New	+$150K	0.01%	293

K2 Principal Fund's DMAQR Position: Q1 2024 in Review

K2 Principal Fund sold out of Deep Medicine Acquisition Corp. Rights (DMAQR) in Q1 2024, closing a stake of 134,514 shares — an estimated $40.4K sold.

K2 Principal Fund first reported a position in DMAQR in Q4 2021 and held it in 9 quarters. The position peaked at $152K in Q4 2021. 0 funds tracked by Wall St. Rank hold DMAQR as of Q1 2024.

K2 Principal Fund reported no remaining Deep Medicine Acquisition Corp. Rights position as of Q1 2024 after selling out during the quarter.
K2 Principal Fund sold 134,514 Deep Medicine Acquisition Corp. Rights shares in Q1 2024, an estimated $40.4K.
K2 Principal Fund first reported a position in Deep Medicine Acquisition Corp. Rights in Q4 2021 and held it in 9 quarters.
K2 Principal Fund's Deep Medicine Acquisition Corp. Rights position peaked at $152K in Q4 2021.
0 funds tracked by Wall St. Rank held Deep Medicine Acquisition Corp. Rights as of Q1 2024.

Based on K2 Principal Fund's 13F filing for Q1 2024, filed 14 May 2024.